The New Year could be an interesting year for the CLL group for all sorts of reasons, but the main focus remains on conducting high quality research. The last year ended with the great news that two more papers from the group had been accepted for publication. Both papers involved the study of prognostic markers in untreated CLL patients, and suggest immune or tumour cell markers that correlate with disease progression.
Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Nunes CT, Wong R, Mason M, Fegan C, Man S, Pepper C. Clin Cancer Res. 2011 Dec 21. [Epub ahead of print]
Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Pepper C, Majid A, Lin TT, Hewamana S, Pratt G, Walewska R, Gesk S, Siebert R, Wagner S, Kennedy B, Miall F, Davis ZA, Tracy I, Gardiner AC, Brennan P, Hills RK, Dyer MJ, Oscier D, Fegan C. Br J Haematol. 2011 Dec 15. doi: 10.1111/j.1365-2141.2011.08974.x. [Epub ahead of print]